17,261 trials
Epidermolysis Bullosa · Pruritus
Primary: Comparative Weekly Change in NRS Itch Score Over the 8-week Active Treatment Period — -2; -1 score/week comparative change
Irritable Bowel Syndrome
Primary: Within and Between Group Comparisons of Disease Severity as Determined by Irritable Bowel Syndrome-Symptom Severity Score (IBS-SSS) — 282; 309; 221; 236 units on a scale
Migraine
Primary: Headache Severity — 2.00; 2.00 score on a scale
Lateral Epicondylitis
Primary: Elbow Pain Assessments (VAS), Treated Subjects — 76.6; 77.7; 75.9; 72 score on a scale
Chronic Kidney Disease · Cystic Kidney Disease
Primary: Number of Lesions With a Change in Radiologist's Evaluation — 24 lesions
Coronary Artery Disease
Primary: Statistical Analysis of Change From Baseline to Day 3 in Myocardial Perfusion Endpoints Compared With Mid Perfusion Reserve Index Using ANCOVA End Points — -0.244…
Anaphylaxis · Hypotension · Bronchospasm
Primary: Reduction in the Number and Timing of Anaphylactic Events in Subjects With a History of Frequent Idiopathic Anaphylaxis. — 32; 6 percentage of change of events
Diffuse Large B-Cell Lymphoma · Follicular Lymphoma
Primary: Phase 1b/2 : Overall Response Rate of Number of Participants — 7; 8 Participants
Crohn's Disease
Primary: Percentage of Participants With Remission at Week 8 — 13.3; 23.1; 14.3; 19.5 percentage of participants — p=0.76
IGA Nephropathy
Primary: Mean Change of Proteinuria as Measured by Spot Urine Protein/Creatinine Ratio (sPCR) at Week 24 — -157.5; -577.2; -177.4 mg/g — p=0.97
Liposarcoma
Primary: Confirmed Overall Response Rate Per the RECIST 1.1 Criteria — 0 percentage of patients
Ulcerative Colitis
Primary: Percentage of Participants With Remission at Week 8 — 4.3; 0.0; 2.5; 13.3 percentage of participants — p=0.021
Non-Alcoholic Steatohepatitis (NASH)
Primary: Number of Participants Who Experienced Treatment-Emergent Adverse Events (TEAEs), Treatment-Emergent Serious Adverse Events (SAEs), and Any Grade ≥ 1 Laboratory…
Squamous Cell Cancer · Head and Neck Cancer
Primary: Phase II Recommended Dose for the Combination of Temsirolimus + Weekly Paclitaxel + Carboplatin. — 25 mg
Acute Biphenotypic Leukemia · de Novo Myelodysplastic Syndrome · Previously Treated Myelodysplastic Syndrome
Primary: Number of Participants With Dose Limiting Toxicities of Mitoxantrone (Phase I, Dose Level 4) — 1; 2 Participants